Arcus Biosciences
RCUS
64 hedge funds and large institutions have $274M invested in Arcus Biosciences in 2018 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 13 increasing their positions, 11 reducing their positions, and 22 closing their positions.
32% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 22
18% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 11
12% more funds holding
Funds holding: 57 → 64 (+7)
3.72% more ownership
Funds ownership: 46.66% → 50.38% (+3.7%)
6% less capital invested
Capital invested by funds: $293M → $274M (-$18.6M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$35.8M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.96M |
| 3 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
+$5.37M |
| 4 |
BlackRock
New York
|
+$4.95M |
| 5 |
JP Morgan Chase
New York
|
+$4.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$5.57M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$4.86M |
| 3 |
Millennium Management
New York
|
-$2.8M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$2.59M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$1.6M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ZP
76
Zimmer Partners
New York
| – | -$154K | -10,000 | Closed |
|
|
PHK
77
Point72 Hong Kong
Hong Kong
| – | -$118K | -7,656 | Closed |
|
|
DCM
78
DAFNA Capital Management
Los Angeles,
California
| – | -$116K | -7,500 | Closed |
|
|
AAMU
79
Amundi Asset Management US
Boston,
Massachusetts
| – | -$69K | -4,445 | Closed |
|
80
CIBC Private Wealth Group
Atlanta,
Georgia
| – | -$23K | -1,500 | Closed |
|
|
FANJ
81
Financial Architects (New Jersey)
Marlton,
New Jersey
| – | -$19K | -1,200 | Closed |
|
|
FPFS
82
First Personal Financial Services
Charlotte,
North Carolina
| – | -$5K | -296 | Closed |
|
|
CCA
83
Catalyst Capital Advisors
Huntington,
New York
| – | -$4K | -247 | Closed |
|
|
SPIA
84
Steward Partners Investment Advisory
New York
| – | -$3K | -200 | Closed |
|
85
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$314 | +20 | New |
|
86
Bank of Montreal
Toronto,
Ontario, Canada
| – | +$581 | +37 | New |
|
RCUS Hedge Fund Activity: Q2 2018 in Review
64 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q2 2018, worth a combined $274M — down 6.4% from $293M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new RCUS positions and 22 closed out — a net gain of 7 holders — while 13 added to existing stakes and 11 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $35.8M. The largest seller was Foresite Capital Management IV, cutting an estimated $5.57M.
- 64 institutional investors held Arcus Biosciences (RCUS) as of Q2 2018, up from 57 in Q1 2018.
- Funds reported $274M of Arcus Biosciences stock for Q2 2018, down 6.4% quarter-over-quarter.
- 29 funds opened new Arcus Biosciences positions in Q2 2018 and 22 closed out, a net change of +7 holders.
- The largest Arcus Biosciences buyer in Q2 2018 was Wellington Management Group, an estimated $35.8M added.
- The largest Arcus Biosciences seller in Q2 2018 was Foresite Capital Management IV, an estimated $5.57M sold.
Based on aggregated 13F filings for Q2 2018.